OBJECTIVE AND DESIGN: Angiotensin-converting enzyme 2 (ACE2) is expressed in gastrointestinal tissue. Previous studies of GL1001, a potent and selective ACE2 inhibitor, have revealed anti-inflammatory activity in the mouse digestive tract. We hypothesized that GL1001 might also produce beneficial effects in a mouse DSS model of inflammatory bowel disease. MATERIALS: Female mice were used for study. TREATMENT: Animals were treated for 5 days with 5% DSS in the drinking water to induce colitis. For the following 9 days, animals were treated twice daily with GL1001 (30, 100, 300 mg/kg, s.c.), sulfasalazine (150 mg/kg, p.o.), or vehicle. METHODS: Throughout the experiment, body weight, rectal prolapse, stool consistency, and fecal occult blood were monitored. At termination, colon length, histopathology, and myeloperoxidase activity were assessed. RESULTS: High-dose GL1001 ameliorated DSS-induced disease activity, including rectal prolapse and intestinal bleeding. The most robust effect of GL1001 was observed 48-96 h post DSS treatment and was comparable in magnitude to that of sulfasalazine. Colon pathology and myeloperoxidase activity were also markedly attenuated by high-dose GL1001 treatment, with the most profound effects observed in the distal segment. CONCLUSIONS: The findings support the previously observed anti-inflammatory effects of ACE2 inhibition in gastrointestinal tissue and suggest that GL1001 may have therapeutic utility for inflammatory bowel disease.
OBJECTIVE AND DESIGN:Angiotensin-converting enzyme 2 (ACE2) is expressed in gastrointestinal tissue. Previous studies of GL1001, a potent and selective ACE2 inhibitor, have revealed anti-inflammatory activity in the mouse digestive tract. We hypothesized that GL1001 might also produce beneficial effects in a mouse DSS model of inflammatory bowel disease. MATERIALS: Female mice were used for study. TREATMENT: Animals were treated for 5 days with 5% DSS in the drinking water to induce colitis. For the following 9 days, animals were treated twice daily with GL1001 (30, 100, 300 mg/kg, s.c.), sulfasalazine (150 mg/kg, p.o.), or vehicle. METHODS: Throughout the experiment, body weight, rectal prolapse, stool consistency, and fecal occult blood were monitored. At termination, colon length, histopathology, and myeloperoxidase activity were assessed. RESULTS: High-dose GL1001 ameliorated DSS-induced disease activity, including rectal prolapse and intestinal bleeding. The most robust effect of GL1001 was observed 48-96 h post DSS treatment and was comparable in magnitude to that of sulfasalazine. Colon pathology and myeloperoxidase activity were also markedly attenuated by high-dose GL1001 treatment, with the most profound effects observed in the distal segment. CONCLUSIONS: The findings support the previously observed anti-inflammatory effects of ACE2 inhibition in gastrointestinal tissue and suggest that GL1001 may have therapeutic utility for inflammatory bowel disease.
Authors: Miriam Granado; Teresa Priego; Ana I Martín; M Angeles Villanúa; Asunción López-Calderón Journal: Am J Physiol Endocrinol Metab Date: 2004-10-26 Impact factor: 4.310
Authors: Hyung J Chun; Ziad A Ali; Yoko Kojima; Ramendra K Kundu; Ahmad Y Sheikh; Rani Agrawal; Lixin Zheng; Nicholas J Leeper; Nathan E Pearl; Andrew J Patterson; Joshua P Anderson; Philip S Tsao; Michael J Lenardo; Euan A Ashley; Thomas Quertermous Journal: J Clin Invest Date: 2008-10 Impact factor: 14.808
Authors: Song Han; Guiyun Wang; Suimin Qiu; Carol de la Motte; Hui-Qun Wang; Guillermo Gomez; Ella W Englander; George H Greeley Journal: Regul Pept Date: 2007-02-22
Authors: Sarah E Sansom; Gerard J Nuovo; Mickey M Martin; Sainath R Kotha; Narasimham L Parinandi; Terry S Elton Journal: Am J Physiol Gastrointest Liver Physiol Date: 2010-06-17 Impact factor: 4.052
Authors: Jeffrey D Jacobs; Thomas Wagner; George Gulotta; Chuanhong Liao; Yan Chun Li; Marc Bissonnette; Joel Pekow Journal: Dig Dis Sci Date: 2019-02-06 Impact factor: 3.487